- Home
- C vs GILD Comparison
C vs GILD Comparison
Compare C & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- C
- GILD
- Stock Information
- Founded
- C 1812
- GILD 1987
- Country
- C United States
- GILD United States
- Employees
- C N/A
- GILD N/A
- Industry
- C Major Banks
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- C Finance
- GILD Health Care
- Exchange
- C Nasdaq
- GILD Nasdaq
- Market Cap
- C 163.6B
- GILD 138.7B
- IPO Year
- C N/A
- GILD 1992
- Fundamental
- Price
- C $93.41
- GILD $108.22
- Analyst Decision
- C Buy
- GILD Buy
- Analyst Count
- C 15
- GILD 24
- Target Price
- C $95.83
- GILD $110.95
- AVG Volume (30 Days)
- C 16.6M
- GILD 7.3M
- Earning Date
- C 07-15-2025
- GILD 08-07-2025
- Dividend Yield
- C 2.40%
- GILD 2.92%
- EPS Growth
- C 87.24
- GILD 1118.07
- EPS
- C 6.76
- GILD 4.73
- Revenue
- C $73,325,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- C $19.93
- GILD $1.69
- Revenue Next Year
- C $3.20
- GILD $3.67
- P/E Ratio
- C $13.82
- GILD $22.87
- Revenue Growth
- C 5.26
- GILD 4.68
- 52 Week Low
- C $53.51
- GILD $70.78
- 52 Week High
- C $93.80
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- C 78.09
- GILD 45.98
- Support Level
- C $85.62
- GILD $109.45
- Resistance Level
- C $91.80
- GILD $114.87
- Average True Range (ATR)
- C 1.89
- GILD 2.23
- MACD
- C 0.42
- GILD -0.45
- Stochastic Oscillator
- C 95.76
- GILD 2.64
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).